Aandelen in “Gezondheidstechnologie”

Aandeel Datum Koers Evolutie
vlag Qiagen NV 6/02 50,950 USD
-0,55% 		-0,55%
vlag Quanterix Corp 6/02 6,090 USD
+3,57% 		+3,57%
vlag Quantum Genomics 24/10 0,072 EUR
-1,77% 		-1,77%
vlag Quest Pharmatech, Inc. 5/02 0,030 CAD
-14,29% 		-14,29%
vlag QuidelOrtho Corp. 6/02 29,100 USD
+1,43% 		+1,43%
vlag Quince Therapeutics Inc 6/02 0,139 USD
-4,86% 		-4,86%

Nieuws over “Gezondheidstechnologie”

16:23 · INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics · Persbericht

16:23 · INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics · Persbericht

6/02 · Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery · Persbericht

6/02 · Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE) · Persbericht

6/02 · Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation · Persbericht

6/02 · uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease · Persbericht

6/02 · VALNEVA Declaration of shares and voting rights: January 31, 2026 · Persbericht

6/02 · Coloplast A/S - Interim Financial Report, Q1 2025/26 · Persbericht

5/02 · Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 · Persbericht

5/02 · Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 · Persbericht

5/02 · Envista Reports Fourth Quarter 2025 Results · Persbericht

5/02 · Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons · Persbericht

5/02 · Guerbet : 2025 revenue. · Persbericht

5/02 · Virbac : Declaration of the number of shares and voting rights 01/2026 · Persbericht

5/02 · Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers · Persbericht

5/02 · $207B Market Shift: The Race for Fast Track Approval in Oncology · Persbericht

5/02 · Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program · Persbericht

5/02 · Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets · Persbericht

5/02 · PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 · Persbericht

5/02 · COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING · Persbericht

5/02 · Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 · Persbericht

Mijn selecties